Shares of Allakos Inc (NASDAQ:ALLK) hit a new 52-week high during trading on Tuesday . The company traded as high as $58.91 and last traded at $57.65, with a volume of 2117 shares traded. The stock had previously closed at $55.83.

A number of brokerages have recently commented on ALLK. Zacks Investment Research cut Allakos from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. Jefferies Financial Group began coverage on Allakos in a research report on Monday, August 13th. They issued a “buy” rating and a $53.00 price target on the stock. William Blair began coverage on Allakos in a research report on Monday, August 13th. They issued an “outperform” rating on the stock. Finally, Goldman Sachs Group began coverage on Allakos in a research report on Monday, August 13th. They issued a “neutral” rating and a $31.00 price objective on the stock.

Allakos (NASDAQ:ALLK) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, sell-side analysts forecast that Allakos Inc will post -1.07 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ALLK. NEA Management Company LLC bought a new position in Allakos in the 3rd quarter valued at approximately $102,046,000. FMR LLC bought a new position in Allakos in the 3rd quarter valued at approximately $92,063,000. BlackRock Inc. bought a new position in Allakos in the 3rd quarter valued at approximately $30,938,000. Jennison Associates LLC bought a new position in Allakos in the 3rd quarter valued at approximately $15,378,000. Finally, Alliancebernstein L.P. bought a new position in Allakos in the 3rd quarter valued at approximately $14,473,000. 0.35% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/11/13/allakos-allk-reaches-new-12-month-high-at-58-91.html.

Allakos Company Profile (NASDAQ:ALLK)

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Read More: Do stock splits help investors?

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.